Skip to main
APYX

APYX Stock Forecast & Price Target

APYX Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Apyx Medical Corp is experiencing a positive momentum in its financial outlook, highlighted by an anticipated Surgical Aesthetics revenue of $43.0 million to $45.0 million, reflecting a year-over-year growth of 14% at the midpoint, and an upward revision of full-year revenue guidance to $50.5 million to $52.5 million due to improved operational execution and demand trends. The company has reported a 12% increase in revenue for the latest quarter, largely driven by a 19% surge in Surgical Aesthetics, which is linked to the successful launch of the AYON Body Contouring System and increased single-use handpiece sales. Furthermore, the ongoing adoption of GLP-1 weight-loss drugs is expected to enhance demand for surgical procedures aimed at skin tightening, further supporting Apyx's growth trajectory and revenue estimates for FY2026, which have been increased to $58.0 million.

Bears say

Apyx Medical Corp has revised its guidance for OEM sales down to approximately $7.5 million, reflecting a decline in sales volumes to existing customers and signaling potential struggles in maintaining revenue streams. The company's stock price has suffered since its peak in September 2021 due to ongoing challenges such as a prior FDA warning letter and increased competition from the rising utilization of GLP-1 medications, which may shift consumer spending away from aesthetic procedures. Additionally, the company's cash position has decreased from $29.3 million to $25.1 million in the third quarter, illustrating financial strain amid various operational risks, including regulatory hurdles and macroeconomic pressures within the cash-pay aesthetics market.

APYX has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Apyx Medical Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Apyx Medical Corp (APYX) Forecast

Analysts have given APYX a Buy based on their latest research and market trends.

According to 2 analysts, APYX has a Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Apyx Medical Corp (APYX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.